
WalletHub recently compared the most populated US cities to see which ones prioritize residents’ well-being. Find out which areas ranked healthiest and unhealthiest.

Editor of Patient Care Online.

WalletHub recently compared the most populated US cities to see which ones prioritize residents’ well-being. Find out which areas ranked healthiest and unhealthiest.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

If EUA is granted, the Novavax COVID-19 vaccine would be the first protein-based COVID-19 vaccine available in the US.

ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

New research shows excessive alcohol use is strongly associated with an increased risk for colorectal cancer, regardless of genetic risk.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Compared to persons without evidence of prior infection, survivors are significantly more likely to experience conditions often attributable to post-COVID.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Lead author of a recent study discusses why clinicians may be hesitant to use TikTok and how social media may shape health care going forward.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Topline data showed that a third dose of the Pfizer-BioNTech vaccine was well tolerated among children with a safety profile similar to placebo.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Dupilumab is approved for the treatment of eosinophilic esophagitis in patients aged ≥12 years weighing at least 40 kgs.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.